Equities analysts forecast that Orgenesis Inc. (NYSE:ORGS) will report earnings of ($0.23) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Orgenesis’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.31). Orgenesis reported earnings per share of ($0.52) during the same quarter last year, which indicates a positive year over year growth rate of 55.8%. The company is scheduled to announce its next quarterly earnings results on Monday, April 29th.

According to Zacks, analysts expect that Orgenesis will report full year earnings of ($0.53) per share for the current year, with EPS estimates ranging from ($0.60) to ($0.45). For the next fiscal year, analysts forecast that the company will post earnings of ($0.17) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Orgenesis.

Orgenesis (NYSE:ORGS) last released its quarterly earnings results on Wednesday, February 13th. The company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.18). The firm had revenue of $5.80 million for the quarter, compared to the consensus estimate of $7.78 million.

Shares of NYSE:ORGS traded down $0.17 during trading on Tuesday, reaching $4.63. The stock had a trading volume of 43,700 shares, compared to its average volume of 33,270. Orgenesis has a 52 week low of $3.87 and a 52 week high of $10.49.

About Orgenesis

Orgenesis Inc, a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. It operates through two segments, Contract Development and Manufacturing Organizations (CDMO) and Cellular Therapy (CT) Business.

Further Reading: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Orgenesis (ORGS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.